SCHEMBL4968151

SCHEMBL4968151

CN(c1cnc[nH]1)c1cc2c(Nc3ccc(F)c(Cl)c3)c(C#N)cnc2cc1OC(F)(F)F

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 15/20 0.59
ERBB2 P04626 8/20 0.59
MAP3K8 P41279 7/20 0.54
MAPK14 Q16539 2/20 0.54
MAPK13 O15264 1/20 0.54
MAPK12 P53778 1/20 0.54
MAPK11 Q15759 1/20 0.54
SRC P12931 3/20 0.49
IKBKB O14920 1/20 0.49
MMP3 P08254 1/20 0.49
CYP3A4 P08684 1/20 0.49
PRKCA P17252 1/20 0.49
PRKACA P17612 1/20 0.49
PRKACG P22612 1/20 0.49
PRKACB P22694 1/20 0.49
MAPKAPK2 P49137 1/20 0.49
STK25 O00506 1/20 0.48
CIT O14578 1/20 0.48
CHEK1 O14757 1/20 0.48
GAK O14976 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6071772 0.91 EGFR (0.71) EGFRERBB2MAP3K8MAPK14MAPK13
SCHEMBL4967268 0.89 EGFR (0.59) EGFRERBB2MAP3K8MAPK14MAPK13
SCHEMBL6072001 0.89 EGFR (0.59) EGFRERBB2MAP3K8MAPK14MAPK13
SCHEMBL6070981 0.83 MAP3K8 (0.73) EGFRERBB2MAP3K8MAPK14MAPK13
SCHEMBL4964899 0.81 MAP3K8 (0.54) EGFRERBB2MAP3K8MAPK14MAPK13
SCHEMBL4965565 0.81 MAP3K8 (0.53) EGFRERBB2MAP3K8MAPK14MAPK13
SCHEMBL6071783 0.81 MAP3K8 (0.57) EGFRERBB2MAP3K8MAPK14MAPK13
SCHEMBL4968159 0.80 MAP3K8 (0.72) EGFRERBB2MAP3K8MAPK14MAPK13
SCHEMBL27728124 0.80 EGFR (0.69) EGFRERBB2MAP3K8SRC
SCHEMBL6072168 0.79 MAP3K8 (0.52) EGFRERBB2MAP3K8MAPK14MAPK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101223143-A 3-cyanoquinoline inhibitors of TPL2 kinase and methods of making and using the same WYETH CORP (US) 2008-07-16 CN disclosed
EP-1888529-A2 3-CYANOQUINOLINE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME Wyeth (US) 2008-02-20 EP disclosed
US-20060264460-A1 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same WYETH (US) 2006-11-23 US disclosed
WO-2006124692-A2 3-CYANOQUINOLINE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264460-A1 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same TNNI3K, CSNK1A1L, CDKL1 EGFR 4122/4885ERBB2 1721/4885MAP3K8 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.